From today, the Australian government will expand Pharmaceutical Benefit Scheme (PBS) access to the drug Keytruda for three additional types of cancer. This is part of a broader shift away from cancer ...
Merck & Co., Inc. is fairly valued after a strong YTD rally, with momentum in Keytruda and Winrevair driving raised guidance. Keytruda's patent cliff in 2028 remains a pivotal risk, but MRK is ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results